BRIEF published on 02/04/2025 at 10:40, 1 year 1 month ago Valerio Therapeutics opts for strategic refocusing Clinical Trials Oncology Financial Strategy Medical Innovation Valerio Therapeutics
PRESS RELEASE published on 02/04/2025 at 10:35, 1 year 1 month ago Inside Information / Other news releases Valerio Therapeutics refocuses strategy, discontinuing clinical trials for financial reasons. Focus on early-stage drug development Clinical Trials Financial Challenges Valerio Therapeutics Strategy Refocus Early-stage Development
BRIEF published on 10/01/2024 at 00:56, 1 year 5 months ago Valerio Therapeutics Reports First Half 2024 Financial Results Financial Results R&D Clinical Trial Valerio Therapeutics Single Domain Antibodies
BRIEF published on 10/01/2024 at 00:45, 1 year 5 months ago Valerio Therapeutics Reports Half-Year 2024 Financial Results and Strategic Updates Financial Results Emglev Acquisition VIO-01 Clinical Trial PlatON™ Platform Therapeutic Innovations
PRESS RELEASE published on 10/01/2024 at 00:40, 1 year 5 months ago Inside Information: News release on accounts, results Valerio Therapeutics reports its half-year 2024 financial results and updates on its activities, including the acquisition of Emglev Therapeutics and progress on the VIO-01 trial Acquisition Financial Results Valerio Therapeutics VIO-01 Trial Emglev Therapeutics
PRESS RELEASE published on 09/30/2024 at 22:40, 1 year 5 months ago Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
BRIEF published on 08/05/2024 at 19:23, 1 year 7 months ago Half-yearly review of the liquidity contract with Kepler Cheuvreux Liquidity Contract Transactions Kepler Cheuvreux AMF Valerio Therapeutics
PRESS RELEASE published on 08/05/2024 at 19:18, 1 year 7 months ago Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract Valerio Therapeutics releases half-year liquidity contract statement revealing shares and trading volumes Liquidity Contract Shares AMF Decision Valerio Therapeutics Trading Volumes
BRIEF published on 06/05/2024 at 07:05, 1 year 9 months ago Minutes of the general meeting of Valerio Therapeutics Biotechnology Voting Results General Meeting Resolutions Valerio Therapeutics
PRESS RELEASE published on 06/05/2024 at 07:00, 1 year 9 months ago Inside Information / Other news releases Valerio Therapeutics reports successful Combined General Meeting with 48.1% quorum, adopting all resolutions. Consolidated vote results and meeting minutes to be available on the Company's website Euronext Growth Paris Biotechnology General Meeting Valerio Therapeutics DDR Drugs
Published on 03/19/2026 at 12:30, 13 minutes ago Algo Grande Launches Advanced Geophysical and Geochemical Programs Ahead of Phase II Drilling in Q2 2026
Published on 03/19/2026 at 12:30, 13 minutes ago Datavault AI Reports First Profitable Quarter, Record Revenue Growth, and Reiterates $200M (~400% YoY Growth) Full Year 2026 Revenue Target
Published on 03/19/2026 at 12:30, 13 minutes ago Gold Basin Resources New Board Of Directors And Management Responds To Helix Joint Venture Announcement
Published on 03/19/2026 at 12:00, 43 minutes ago Galway Metals Intersects 8.6 g/t Gold Over 15.0m Including 110.0 g/t Over 1.0m at Southwest Deposit
Published on 03/19/2026 at 12:00, 43 minutes ago Gamma Resources Announces Debt Settlement and Insider Warrant Exercises
Published on 03/19/2026 at 12:10, 32 minutes ago ZPMC Completes First Emissions Rights Transaction in Shanghai
Published on 03/19/2026 at 12:05, 37 minutes ago CD&R Expands Climate Leadership Program to Europe with Imperial College Business School and Extends Columbia University Partnership in the U.S. for Second Year
Published on 03/19/2026 at 12:00, 43 minutes ago PT Danantara Investment Management opens DPT registration for PSEL partners
Published on 03/19/2026 at 08:45, 3 hours 58 minutes ago Deezer and Sonos renew and expand long-term collaboration
Published on 03/19/2026 at 07:00, 5 hours 43 minutes ago bioMérieux Receives IVDR CE‑Marking for Two BIOFIRE® SPOTFIRE® Panels to Strengthen Near‑Patient Respiratory and Sore Throat Diagnostics Across Europe
Published on 03/19/2026 at 07:00, 5 hours 43 minutes ago 2025 Annual results and new strategic signature
Published on 03/18/2026 at 19:41, 17 hours 1 minute ago Covivio - Conditions of availability of the 2025 Universal Registration Document
Published on 03/18/2026 at 18:00, 18 hours 43 minutes ago Deezer achieves profitability in FY25 as strategy delivers tangible results
